Jennison Associates LLC Intra Cellular Therapies, Inc. Transaction History

Jennison Associates LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	BUY	$64.37 - $75.65 $592,976 - $696,887	9,212 New	9,212 $637,000
Q3 2023 Oct 31, 2023	BUY	$52.09 - $64.1 $1.26 Million - $1.54 Million	24,094 Added 14.8%	186,867 $9.73 Million
Q2 2023 Aug 03, 2023	BUY	$54.67 - $66.44 $8.23 Million - $10 Million	150,480 Added 1224.11%	162,773 $10.3 Million
Q1 2023 Apr 26, 2023	SELL	$43.8 - $56.99 $164,731 - $214,339	-3,761 Reduced 23.43%	12,293 $665,000
Q4 2022 Feb 09, 2023	SELL	$44.07 - $54.45 $55,131 - $68,116	-1,251 Reduced 7.23%	16,054 $849,000
Q3 2022 Nov 01, 2022	BUY	$42.7 - $59.99 $177,375 - $249,198	4,154 Added 31.59%	17,305 $805,000
Q2 2022 Aug 02, 2022	BUY	$43.0 - $65.64 $565,493 - $863,231	13,151 New	13,151 $751,000

398

87.5M

309K

302K

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.07B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.